EMA Grants Final Approval for Chiesi Farmaceutici's Trimbow, a Triple Combination Therapy for COPD
Europe's First Single-Inhaler Triple Combination Therapy Approved
The European Medicines Agency (EMA) approved Chiesi Farmaceutici's Trimbow, a treatment for Chronic Obstructive Pulmonary Disease (COPD), on July 17, 2017. Trimbow is the first triple therapy to combine beclometasone dipropionate (an Inhaled Corticosteroid, ICS), formoterol fumarate dihydrate (a Long-Acting Beta2-Agonist, LABA), and glycopyrronium bromide (a Long-Acting Muscarinic Antagonist, LAMA) into a single inhaler. These drugs target the glucocorticoid receptor, beta-2 adrenergic receptor, and muscarinic acetylcholine receptor M3, respectively, to inhibit airway inflammation and dilate the bronchi. Previously, patients had to use multiple inhalers, which reduced adherence. The approval of Trimbow provides an innovative treatment option that allows patients to control their symptoms with a single inhalation.
Proven Efficacy and Safety in Phase 3 Clinical Trials
This approval is based on the results of the TRILOGY and TRINITY studies, large-scale Phase 3 clinical trials. In the TRILOGY study, Trimbow demonstrated a 23% reduction in the rate of moderate to severe acute exacerbations compared to existing ICS/LABA dual therapy. In the TRINITY study, Trimbow significantly reduced the annual rate of acute exacerbations by 20% compared to tiotropium (a single LAMA therapy) (p=0.003) and improved forced expiratory volume in 1 second (FEV1) by 0.061 liters, fully meeting the primary endpoints (p<0.0001). This strong clinical evidence was a key factor in the regulatory agency's positive assessment of Trimbow's benefit-risk profile.
Competitive Landscape and Positioning in the COPD Market
The global COPD treatment market is currently estimated at $13 billion to $29 billion and is expected to continue to grow with the aging population. Chiesi Farmaceutici has proactively entered the triple combination therapy market with Trimbow, but it will soon face strong competition from products such as GSK's Trelegy Ellipta and AstraZeneca's Breztri Aerosphere. Nevertheless, Chiesi Farmaceutici has established a strong position in the market, with its respiratory product line, the 'Air' franchise, generating €1.886 billion in sales in 2025. In particular, Trimbow has a differentiated competitive advantage due to its use of extrafine particle formulation technology, which delivers the drug deep into the lungs.
Market Access Barriers and Long-Term Prospects
In the European market, obtaining reimbursement from national health authorities is a critical step in ensuring market access after regulatory approval. Market penetration rates may vary depending on the budgetary situation and cost-effectiveness assessments of each country, so it is important to closely monitor the pricing policies of each country. Chiesi Farmaceutici is expanding the indications for Trimbow to include asthma, starting in Europe, to create long-term growth drivers, which will have a positive impact on the company's sustainable cash flow generation. As the adoption of global triple combination therapy as a standard of care accelerates, the company's long-term sales growth is expected to accelerate further.
Chiesi Farmaceutici's Trimbow, Europe's first single-inhaler triple combination therapy for COPD, is leading a paradigm shift in the standard of care, demonstrating a 23% reduction in acute exacerbation rates compared to existing dual therapies based on Phase 3 clinical data. In the global COPD treatment market, estimated at $13 billion to $29 billion, single-inhaler triple therapies have the potential to rapidly expand market share by significantly improving patient adherence. In the short term, the speed of reimbursement listing in each European country will be a key determinant of sales visibility, and in the medium to long term, differentiation based on original extrafine technology will be required in the competitive landscape with GSK's Trelegy and AstraZeneca's Breztri. This approval is expected to serve as an important benchmark for researchers and pharmaceutical companies developing multi-mechanism combination therapies in the field of respiratory disease, influencing their regulatory and clinical trial design strategies.
Source: EMA (ema)